These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Devroey D; Velkeniers B; Duquet W; Betz W Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669 [TBL] [Abstract][Full Text] [Related]
64. Effects of ezetimibe on atherosclerosis in preclinical models. Davis HR; Lowe RS; Neff DR Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230 [TBL] [Abstract][Full Text] [Related]
65. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. Miyoshi T; Nakamura K; Doi M; Ito H Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669 [TBL] [Abstract][Full Text] [Related]
66. HDL cholesterol: reappraisal of its clinical relevance. März W; Kleber ME; Scharnagl H; Speer T; Zewinger S; Ritsch A; Parhofer KG; von Eckardstein A; Landmesser U; Laufs U Clin Res Cardiol; 2017 Sep; 106(9):663-675. PubMed ID: 28342064 [TBL] [Abstract][Full Text] [Related]
67. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665 [TBL] [Abstract][Full Text] [Related]
68. [The history of treatment lipid metabolism disorders]. Bernschneider-Reif S Pharm Unserer Zeit; 2007; 36(2):88-97. PubMed ID: 17424993 [No Abstract] [Full Text] [Related]
69. After 40 years of cholesterol-watching. Ahrens EH J Lipid Res; 1984 Dec; 25(13):1442-9. PubMed ID: 6397552 [No Abstract] [Full Text] [Related]
70. Atherosclerosis and carcinoma: Two facets of dysfunctional cholesterol homeostasis. Chandra NC J Biochem Mol Toxicol; 2020 Dec; 34(12):e22595. PubMed ID: 32761975 [TBL] [Abstract][Full Text] [Related]
71. From gallstones to genes: two hundred years of sterol research. A tribute to George J. Schroepfer Jr. Gibbons GF Lipids; 2002 Dec; 37(12):1153-62. PubMed ID: 12617469 [TBL] [Abstract][Full Text] [Related]
72. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. Steinberg D J Lipid Res; 2013 Nov; 54(11):2946-9. PubMed ID: 23975896 [TBL] [Abstract][Full Text] [Related]
73. [Programs for Continuing Medical Education: B session; 1. Pathogenesis of atherosclerosis and an approach to reduce cardiovascular events]. Hirata K Nihon Naika Gakkai Zasshi; 2016 Mar; 105(3):471-6. PubMed ID: 27319195 [No Abstract] [Full Text] [Related]
75. Targeting New Players Offers us Novel Strategic Approaches but may also Lead us to Labyrinth in Highly Integrated Networks for Gene Regulation. Yokoyama S J Atheroscler Thromb; 2022 Feb; 29(2):148-149. PubMed ID: 33518554 [No Abstract] [Full Text] [Related]
76. Cholesterol controversy: considerations for mouse models of atherosclerosis. Tedgui A Cardiovasc Res; 2018 Dec; 114(14):1907. PubMed ID: 30445558 [No Abstract] [Full Text] [Related]
78. Research Progress on the Relationship between Atherosclerosis and Inflammation. Zhu Y; Xian X; Wang Z; Bi Y; Chen Q; Han X; Tang D; Chen R Biomolecules; 2018 Aug; 8(3):. PubMed ID: 30142970 [TBL] [Abstract][Full Text] [Related]
79. Atherosclerosis: the interplay between lipids and immune cells. Schaftenaar F; Frodermann V; Kuiper J; Lutgens E Curr Opin Lipidol; 2016 Jun; 27(3):209-15. PubMed ID: 27031276 [TBL] [Abstract][Full Text] [Related]
80. Animal models of atherosclerosis. Emini Veseli B; Perrotta P; De Meyer GRA; Roth L; Van der Donckt C; Martinet W; De Meyer GRY Eur J Pharmacol; 2017 Dec; 816():3-13. PubMed ID: 28483459 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]